Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. RI BioHistory (TM)
Career
Job Search Post a Job Destination RI
News/Events
Industry News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Drug Development Resources
Education
K-12 Higher Ed BioEd Reading
About
Advertising Feedback Home
 
About
 Advertising
 Feedback
 Home
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
Community Service Ad: Athena Partners - Eliminating women's cancers
Advertising
 
Jobs
 

ORCA Monthly Meeting: March 16 - Requirements & Best Practices for Management Review

Conference on Biosimilars, University of Washington, Seattle - March 19-20. Sign up today!



BioHistory Moment: Iditarod Trail used to transport diphtheria serum to Nome.

Balto

In 1925, a life-or-death race to save the children of Nome from a diphtheria epidemic made an international hero of one sled dog, and led to the creation of Alaska's Iditarod sled dog race. A diphtheria epidemic threatened remotely located Nome, and air transportation was unavailable to transport serum from Anchorage nearly a thousand miles away.

The solution: A relay of dog teams transported serum on the Iditarod Trail from Nenana to Nome, and every village enroute provided its best team and driver for the next leg continually moving the serum toward Nome. Gunnar Kaasen, a Norwegian musher, drove the final two legs into Nome behind his lead dog Balto through a blizzard with 80 mph winds to deliver 300,000 units of diphtheria antitoxin to Dr. Curtis Welch, the only doctor in Nome.

The serum arrived in time, prevented the epidemic and saved hundreds of lives. The 20 mushers had covered nearly 700 miles in slightly more than 127 hours in temperatures of minus40° Fahrenheit below zero and strong winds. The serum run received worldwide press coverage and the mushers received special gold medals and other recognition. In 1926, a statue of Balto, the heroic lead dog, was erected in New York's Central Park.

More...

Learn about Seattle's Life Science Incubator Facility

PNDRI Building, First Hill, Seattle, WA. Seattle's Life Science Incubator Research facility was commissioned in 1988, and is a contemporary-designed building provided with modern research systems. Four floors are specifically laboratory space, one floor is a fully equipped vivarium and one floor is clinical space and management offices. The faciility is centrally located in close proximity to downtown Seattle, the University of Washington, the Fred Hutchinson Cancer Research Center, and more.

Learn about this and other biotechnology, medical device and pharmaceutical facilities available for sale, lease or sublease in Rhode Island, regionally or nationwide.

More...

(Advertising)


Industry News...

    Free News Release Posting & Archiving Service


  • GTC Biotherapeutics reports fourth quarter and fiscal year end 2009 financial results  The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.
    GTC Biotherapeutics, Inc.  March 12, 2010  


  • Progenics to advance oral methylnaltrexone into late stage clinical development  Progenics Pharmaceuticals announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010.
    Progenics Pharmaceuticals, Inc.  March 12, 2010  


  • FDA's Black Box Warning addressed by Genelex's PlavitestT  The FDA added a new black box warning to Plavix, pointing out the importance of individual patient genetics in determining the effectiveness of Plavix treatment. The relabeling is in response to clinical research demonstrating that one-third of patients are in varying degrees of treatment failure.
    Genelex Corporation  March 12, 2010  


  • Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
    Pfizer Inc.  March 11, 2010  


  • Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
    Pfizer Inc.  March 11, 2010  


More... | Submit News Release | Advertising...

News

New Job Postings...

Free Job Posting Trial Offer
  • Corporate Communications Specialist Seattle Genetics, Inc. (WA)
  • Scientist/Senior Scientist, Formulations Seattle Genetics, Inc. (WA)
  • Quality Assurance Validation Associate Seattle Genetics, Inc. (WA)
  • Quality Assurance Manufacturing Associate Seattle Genetics, Inc. (WA)
  • Drug Safety Specialist Seattle Genetics, Inc. (WA)
More... | Job Advertising... | About Job Postings...
ESL Speaking

New Facilities Available...

ATC clean room constructors...validation guaranteed!
  • 890 Embarcadero Road Property -- West Sacramento, CA
  • CompleGen Lab/Office Space -- Seattle, WA
  • Life Sciences Incubator -- Seattle, WA
  • University of Iowa Oakdale Research Park Biotech Building -- Coralville, IA
  • University of Iowa Oakdale Research Park BioVentures Center -- Coralville, IA
More... | Facility Advertising...
Facilities

Upcoming Events...

  • 03/15/2010: Pharmacovigilance
  • 03/16/2010: Pharma & Biotech Supply Chain Asia 2010
  • 03/16/2010: Global health as an Investment Opportunity
  • 03/16/2010: Preparing an R&D Product for Out-Licensing and Due Diligence
  • 03/16/2010: Online Webinar: Understanding Disinfectant Qualification
More... | Submit Event | Event Advertising...
Master's Degree in Biomedical Regulatory Affairs

Learn About Rhode Island's BioHistory

Learn About Rhode Island's BioHistory Why is there a life science industry in Rhode Island? Is the industry growing? What do other states have?

Through Rhode Island BioHistory, you can learn about the scientists, institutions, political leaders, and significant events that have shaped and are still shaping the biotechnology, medical device and life science industry in Rhode Island.

More...

BioEvolution Posters

WA BioEvolution 2008 Poster

More More...


March - National Colorectal Cancer Awareness Month

National Colorectal Cancer Awareness Month

As a leading health organization for 25 years, the Prevent Cancer Foundation, the vision of Carolyn Aldigé, has catapulted cancer prevention to prominence and provided more than $113 million in support of cancer prevention and early detection research, education and community outreach programs across the country.

More...


BioFact

(1895) - A German company, Hochst am Main, sells Nitragin, the first commercially cultured Rhizobia isolated from root nodules.


It's a Small World

  Salmonella Typhimurium Salmonella Typhimurium  

Science Quote

"The joy of discovery is certainly the liveliest that the mind of man can ever feel."

-  Claude Bernard, French physiologist
 (1813-78)

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 2010 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advisory Board . Advertising

RhodeIslandLifeScience.com, owned and published by Info.Resource, Inc., is a resource
for the life science industry in the state of Rhode Island.